| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
Serum MMP-2 level correlated with tumor grade and the extent of bone metastases in prostate cancer (PCa) with bone metastases. We determined that the additive effect of zoledronic acid (ZA) on serum PSA and bone turnover markers changes for hormone-sensitive PCa patients with bone metastasis treated by combined androgen blockade (CAB). The addition of ZA to CAB therapy showed PSA and ALP response compared with CAB therapy only, suggesting a potential antitumor effect of ZA in the management of metastatic PCa patients.
Furthermore, to clarify clinical predictors for a PSA decrease >50% in response to alternative non-steroidal antiandrogen therapy (AA) and to develop a nomogram to predict the PSA decrease >50% in response to AA in patients with advanced PCa that relapsed after initial CAB. The receiver operating characteristic curve showed that the accuracy of the predicted probability was 72.5% for the model.
|
